source
- Amgen seeks FDA hearing to keep rare kidney drug Tavneos amid safety concernsAmgen has asked the U.S. Food and Drug Administration for a hearing to argue against a proposed withdrawal of its rare‑disease drug Tavneos. The company submitted a data package containing real‑wo…
- Fatal gene-editing trial in China sparks ethics and oversight concernsA six-year-old girl in China died after receiving an experimental brain-directed CRISPR therapy, according to a report in Science. The tragedy has intensified calls for stronger ethical review and…